Banco Macro SA (ADR) (BMA) Reaches $89.99 After 4.00% Up Move, 0 Analysts Covering Macrocure Ltd (MCUR)

June 20, 2017 - By Kurt Siggers

The stock of Banco Macro SA (ADR) (NYSE:BMA) is a huge mover today! About 166,924 shares traded. Banco Macro SA (ADR) (NYSE:BMA) has risen 43.80% since June 20, 2016 and is uptrending. It has outperformed by 27.10% the S&P500.The move comes after 6 months positive chart setup for the $5.98 billion company. It was reported on Jun, 20 by We have $93.59 PT which if reached, will make NYSE:BMA worth $239.20 million more.

Among 5 analysts covering Macrocure (NASDAQ:MCUR), 0 have Buy rating, 1 Sell and 4 Hold. Therefore 0 are positive. Macrocure had 10 analyst reports since August 10, 2015 according to SRatingsIntel. Credit Suisse reinitiated Macrocure Ltd (NASDAQ:MCUR) on Monday, August 10 with “Outperform” rating. Zacks upgraded the stock to “Hold” rating in Monday, September 7 report. On Thursday, August 20 the stock rating was maintained by Oppenheimer with “Perform”. The firm has “Neutral” rating by Credit Suisse given on Friday, August 21. The rating was downgraded by Jefferies on Friday, August 21 to “Hold”. Credit Suisse downgraded Macrocure Ltd (NASDAQ:MCUR) on Monday, July 18 to “Underperform” rating. The stock has “Neutral” rating by Nomura on Thursday, August 20. The stock of Macrocure Ltd (NASDAQ:MCUR) earned “Hold” rating by Zacks on Tuesday, August 25. See Macrocure Ltd (NASDAQ:MCUR) latest ratings:

It is down 0.00% since June 20, 2016 and is . It has underperformed by 16.70% the S&P500.

Leap Therapeutics Ltd, formerly Macrocure Ltd, is a biotechnology company. The company has market cap of $22.78 million. The Firm is focused on developing, manufacturing and commercializing cell therapy products to address unmet needs for the treatment of chronic wounds, such as diabetic foot ulcers and venous leg ulcers (VLUs). It currently has negative earnings. The Company’s product candidate, CureXcell, is a combination of living human white blood cells that have been activated to facilitate the healing process and stimulate wound closure.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: